Rajesha Rupaimoole
Overview
Explore the profile of Rajesha Rupaimoole including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
5562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saxena T, Quan A, Chan E, Kozlova N, Matai L, Lee J, et al.
Proc Natl Acad Sci U S A
. 2025 Mar;
122(10):e2415389122.
PMID: 40030013
Long noncoding RNAs (lncRNAs) play numerous roles in cellular biology and alterations in lncRNA expression profiles have been implicated in a variety of cancers. Here, we identify and characterize a...
2.
Mangala L, Wang H, Jiang D, Wu S, Somasunderam A, Volk D, et al.
JCI Insight
. 2021 Apr;
6(7).
PMID: 33793423
No abstract available.
3.
Moreno-Smith M, Halder J, Meltzer P, Gonda T, Mangala L, Rupaimoole R, et al.
J Clin Invest
. 2021 Apr;
131(7).
PMID: 33792569
No abstract available.
4.
Rupaimoole R, Wu S, Pradeep S, Ivan C, Pecot C, Gharpure K, et al.
Nat Commun
. 2020 Jun;
11(1):2867.
PMID: 32493919
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Rupaimoole R, Yoon B, Zhang W, Adams B, Slack F
iScience
. 2020 Feb;
23(2):100878.
PMID: 32062455
MicroRNA-34 (miR-34) is one of the major families of tumor suppressor miRNAs often lost in cancers. Delivery of miR-34a mimics to affected tumors as a therapeutic strategy has been tried...
6.
McGuire M, Herbrich S, Dasari S, Wu S, Wang Y, Rupaimoole R, et al.
EBioMedicine
. 2019 May;
43:127-137.
PMID: 31056473
Background: Investigations into the function of non-promoter DNA methylation have yielded new insights into the epigenetic regulation of gene expression. However, integrated genome-wide non-promoter DNA methylation and gene expression analyses...
7.
Hisamatsu T, McGuire M, Wu S, Rupaimoole R, Pradeep S, Bayraktar E, et al.
Mol Cancer Ther
. 2018 Oct;
18(1):162-172.
PMID: 30305341
For mucinous ovarian cancer (MOC), standard platinum-based therapy is largely ineffective. We sought to identify possible mechanisms of oxaliplatin resistance of MOC and develop strategies to overcome this resistance. A...
8.
Gharpure K, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu S, et al.
Nat Commun
. 2018 Jul;
9(1):2923.
PMID: 30050129
The standard treatment for high-grade serous ovarian cancer is primary debulking surgery followed by chemotherapy. The extent of metastasis and invasive potential of lesions can influence the outcome of these...
9.
Mangala L, Wang H, Jiang D, Wu S, Somasunderam A, Volk D, et al.
JCI Insight
. 2018 Jun;
3(11).
PMID: 29889661
No abstract available.
10.
Gharpure K, Lara O, Wen Y, Pradeep S, LaFargue C, Ivan C, et al.
Oncotarget
. 2018 Jun;
9(38):25115-25126.
PMID: 29861857
Primary debulking surgery followed by adjuvant chemotherapy is the standard treatment for ovarian cancer. Residual disease after primary surgery is associated with poor patient outcome. Previously, we discovered ADH1B to...